Partnering in Mental Health Disorders & Neuroscience
Our growing portfolio of partnerships in Mental Health Disorders and Neuroscience aims to address the significant need for new treatments across a range of neuropsychiatric diseases and includes partnerships with both academia and industry. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners.
Our experience
The development of new treatment options in Mental Health Disorders and Neuroscience is a key priority. Our scientists, together with our innovation partners, are pursuing novel therapeutic approaches to address unmet needs across a range of major neuropsychiatric diseases.
Our research focus
We're dedicated to precision psychiatry and redefining mental healthcare to enable people to thrive. Our research approach focuses on developing a deep understanding of the underlying neurobiology of mental health disorders and, by manipulating maladaptive brain circuitry, aims to target the mechanisms directly responsible for major untreated symptom domains in neuropsychiatric diseases. We are also applying this understanding to neurology in nociplastic pain and neurodegeneration.
Our Partnering Interests
Our partnering priorities include:
- Schizophrenia (Cognitive impairment associated with schizophrenia/negative symptoms)
- Depression and anhedonia, Treatment-resistant depression
- Impulsivity and substance abuse disorders
- Bipolar disorders, Borderline personality disorder
- Post-traumatic stress disorder
- Nociplastic pain
- Neurodegeneration.
Our Partners: Warren Center for Neuroscience Drug Discovery at Vanderbilt University
Learn about the ground-breaking science we’re working on with our partners at the Warren Center for Neuroscience discovery and how diversity of thought is driving innovation in this complex area of science.
Related Content
Contact Us
